Skip to main
NVCR

Novocure (NVCR) Stock Forecast & Price Target

Novocure (NVCR) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 17%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

NovoCure Ltd has shown impressive revenue performance, with 4Q25 revenues reaching $174.4 million, representing a 4% quarter-over-quarter increase and an 8% year-over-year growth, driven by strong domestic sales of its Optune Gio device. Additionally, the company has reported notable international growth, particularly with the national reimbursement in Spain expected to enhance revenue streams in 2026. The ongoing clinical trials, including TRIDENT, which has the potential to expand patient access to the Tumor Treating Fields (TTFields) technology, further supports a positive outlook for sustained revenue growth in the coming years.

Bears say

NovoCure Ltd. is facing significant challenges in its revenue projections, with 2026 estimates for glioblastoma (GBM) reduced from $702 million to $690 million, and total revenue expectations cut from $738.9 million to $711.3 million. The company’s efforts in the non-small cell lung cancer (NSCLC) market have been particularly hampered, leading to a decrease in global peak sales estimates to $483 million from $623 million as launch challenges persist. Additionally, considerable risks undermine the company's growth outlook, including potential safety signals from clinical programs, lower-than-expected efficacy, increased competition, regulatory concerns, and issues related to intellectual property protection.

Novocure (NVCR) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 17% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novocure (NVCR) Forecast

Analysts have given Novocure (NVCR) a Buy based on their latest research and market trends.

According to 6 analysts, Novocure (NVCR) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novocure (NVCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.